John Neis
Direttore/Membro del Consiglio presso CELLECTAR BIOSCIENCES, INC.
Patrimonio netto: 19 343 $ in data 31/05/2024
Profilo
John joined Venture Investors in May of 1985 and served as its Executive Managing Director from 2000-2021.
He continues to serve as a Managing Director.
John has extensive experience as a director of portfolio companies, including his current directorships at Cellectar BioSciences, Delphinus Medical Technologies, and Health Scholars.
He has experience in assisting companies from inception to public markets.
He joined the Board of Third Wave Technologies when they had three employees and served through the initial public offering (subsequently acquired by Hologic), and he joined the Board of TomoTherapy when they had one employee and served through their public offering, which was the fourth largest healthcare IPO in the first decade of the millennium.
Other notable past directorships included NimbleGen Systems (acquired by Roche), and Inviragen (acquired by Takeda).
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
14/06/2024 | 6 260 ( 0.02% ) | 19 343 $ | 31/05/2024 |
Posizioni attive di John Neis
Società | Posizione | Inizio |
---|---|---|
CELLECTAR BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 01/02/2008 |
Venture Investors LLC
Venture Investors LLC Investment ManagersFinance Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin. | Investitore di Private Equity | 01/05/1985 |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | Direttore/Membro del Consiglio | - |
Health Scholars, Inc.
Health Scholars, Inc. Information Technology ServicesTechnology Services Health Scholars, Inc. engages as a cloud-based, VR-ready training platform for the management, delivery, and analysis of clinical training. Its solutions include virtual reality training, and simulation management. The company was founded by Brian Gillett in 2017 and is headquartered in Westminster, CO. | Direttore/Membro del Consiglio | - |
Wisconsin Venture Capital Association | Presidente | - |
TAI Diagnostics, Inc.
TAI Diagnostics, Inc. BiotechnologyHealth Technology TAI Diagnostics, Inc. provides biotechnology services. It focuses on developing innovative diagnostic tests for monitoring the health of transplanted organs. The company was founded by Aoy Tomita-Mitchell and Michael E. Mitchell in 2015 and is headquartered in Wauwatosa, WI. | Direttore/Membro del Consiglio | - |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | Direttore/Membro del Consiglio | 21/12/2015 |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | Direttore/Membro del Consiglio | - |
University of Wisconsin Business School | Consulente / Consigliere | - |
Precedenti posizioni note di John Neis
Società | Posizione | Fine |
---|---|---|
░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di John Neis
University of Utah | Undergraduate Degree |
University of Wisconsin | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CELLECTAR BIOSCIENCES, INC. | Health Technology |
Aziende private | 18 |
---|---|
Venture Investors LLC
Venture Investors LLC Investment ManagersFinance Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin. | Finance |
Mithridion, Inc.
Mithridion, Inc. Pharmaceuticals: MajorHealth Technology Mithridion, Inc. develops and manufactures biopharmaceutical products. Its drugs are used for the treatment of Alzheimer's's disease and schizophrenia. The company was founded on November 19, 2004 and is headquartered in Madison, WI. | Health Technology |
TomoTherapy, Inc.
TomoTherapy, Inc. Medical SpecialtiesHealth Technology TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI. | Health Technology |
NimbleGen Systems, Inc.
NimbleGen Systems, Inc. BiotechnologyHealth Technology NimbleGen Systems, Inc. Develops micro-arrays used in bio-technology. It also supplies microarray products and services. The company combines photo-deposition chemistry with digital light projection to shorten array fabrication from months to hours. NimbleGen System was founded in 1999 & is headquartered in Madison, WI. | Health Technology |
Deltanoid Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Deltanoid Pharmaceuticals, Inc. researches and develops therapies for the treatment of human diseases. The firm's focus is to move therapies in a variety of areas, including renal disease, osteoporosis, vitamin D deficiency, and acne through the drug development process and seek partners for later stage development and commercialization. The company was founded by Margaret Clagett-Dame and Hector F. DeLuca in 1999 and is headquartered in Madison, WI. | Commercial Services |
Virent, Inc.
Virent, Inc. Industrial SpecialtiesProcess Industries Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI. | Process Industries |
Wisconsin Technology Council
Wisconsin Technology Council Miscellaneous Commercial ServicesCommercial Services Wisconsin Technology Council provides science and technology advisory services to the Governor and the Legislature. The company was founded in 2001 and is headquartered in Madison, WI. | Commercial Services |
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Commercial Services |
Third Wave Technologies, Inc.
Third Wave Technologies, Inc. BiotechnologyHealth Technology Third Wave Technologies, Inc. developed DNA and RNA detection technology. It provided molecular solutions for clinical, research, and agricultural customers. The company was founded in February 1993 and was headquartered in Madison, WI. | Health Technology |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
Inviragen, Inc.
Inviragen, Inc. BiotechnologyHealth Technology Inviragen, Inc. developed life-saving vaccine to protect against infectious diseases worldwide. The company was founded by Dan T. Stinchcomb and Jorge Osorio in November 2003 and was headquartered in Fort Collins, CO. | Health Technology |
Wisconsin Growth Capital Coalition | |
Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. Medical SpecialtiesHealth Technology Delphinus Medical Technologies, Inc. designs and develops ultrasound imaging devices and components. It offers the SoftVue, a tomographic ultrasound imaging device that scans women's breasts for the presence of masses. The firm supplies it solutions and services to hospitals and imaging clinics. The company also collaborates with imaging equipment manufacturers and distributors with focus on the breast cancer screening market. The company was founded by Neb Duric and Peter J. Littrup in 2009 and is headquartered in Novi, MI. | Health Technology |
TAI Diagnostics, Inc.
TAI Diagnostics, Inc. BiotechnologyHealth Technology TAI Diagnostics, Inc. provides biotechnology services. It focuses on developing innovative diagnostic tests for monitoring the health of transplanted organs. The company was founded by Aoy Tomita-Mitchell and Michael E. Mitchell in 2015 and is headquartered in Wauwatosa, WI. | Health Technology |
Wisconsin Venture Capital Association | |
Prevacept Infection Control, Inc.
Prevacept Infection Control, Inc. Pharmaceuticals: MajorHealth Technology Prevacept Infection Control, Inc. develops and designs pharmaceutical products to eliminate microbial infections. The firm offers B-Lock, an anti-coagulant catheter lock solution with broad spectrum activity against bacterial and fungal microorganisms known to form bio-film structures in indwelling catheters. The company was founded by Krzysztof Appelt and Thomas I. Bradshaw in 2006 and is headquartered in Broomfield, CO. | Health Technology |
Health Scholars, Inc.
Health Scholars, Inc. Information Technology ServicesTechnology Services Health Scholars, Inc. engages as a cloud-based, VR-ready training platform for the management, delivery, and analysis of clinical training. Its solutions include virtual reality training, and simulation management. The company was founded by Brian Gillett in 2017 and is headquartered in Westminster, CO. | Technology Services |
The Morgridge Institute for Research, Inc.
The Morgridge Institute for Research, Inc. Miscellaneous Commercial ServicesCommercial Services The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz. | Commercial Services |
- Borsa valori
- Insiders
- John Neis